DeHeng Advised on ClinBrain's Series B of Financing of 100 Million Scale
2020-09-29
ClinBrain recently announced an investment worth of more than 100 million of yuan in its Series B financing. The lead investor was Genilink Capital which DeHeng represented, followed by Qianhai Fund of Funds, Medfine Capital, and Langcheng Capital.
Founded in 2013, ClinBrain focuses on healthcare big data and integration platforms to provide support for data intelligence in the healthcare industry. It is the first company in China to launch a clinical big data indication discovery system and a clinical big data search engine. It has been granted 71 software copyrights related to medical big data, and applied for 17 invention patents.
As the leader in healthcare big data technology, it boasts a diverse product pipeline, including the "ClinData" series of data middle offices and data governance products with the core of clinical data centers (CDR), operational data centers (ODR), research data centers (RDR), the extract, transform, load of (ETL) healthcare data, healthcare metadata management, master data management, and healthcare data quality management . It also owns the "ClinAPP" series of healthcare data applications and service integration products represented by the clinical big data search engine, clinical research platform for single diseases and cohorts, healthcare data statistical & mining platform, healthcare big data visualization, hospital operation & management, medical service quality management, Patient 360, Medical Workers 360, and the information integration platform HSB.
After this series of financing, it will continue to work on healthcare big data and artificial intelligence, pursue innovation and develop key technologies for more efficient hospital management and better medical services while a lighter burden on patients. It will increase R&D investment to provide intelligent data support for the healthcare industry and promote its development.
The lead investor Genilink Capital, founded by Mr. Jiang Haotian, is a venture capital fund specializing in industry digitalization and TMT hard technology. It firmly invests in innovative tech enterprises, closely tracks emerging growth points related to digital technology across industries, and strives to provide the best support for the most quality entrepreneurs working with them to create the greatest possible long-term success.
As the legal counsel for the deal, the DeHeng team was led by partner Zhang Lei, with primary support from lawyers Zhu Yun and Li Haoyuan. They provided whole-process legal services on behalf of Genilink Capital, including legal due diligence, design and compliance demonstration of the transaction plan, drafting and reviewing of transaction documents, and negotiations. DeHeng lawyers worked closely with project stakeholders, completed the work with professionalism, high efficiency and high quality, and won the trust and recognition of the client.
